Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

MagForce AG. (11/21/14). "Press Release: MagForce AG Successfully Completes Capital Increase at a Price of EUR 6.00 per New Share. Proceeds will be Used to Accelerate Commercialization and to Broaden Product Portfolio ". Berlin.

Organisations Organisation MagForce AG
  Group MagForce (Group)
  Organisation 2 MagForce USA Inc.
  Group MagForce (Group)
Products Product NanoTherm® therapy
  Product 2 investment banking
Index term Index term MagForce–SEVERAL: investment, 201411 capital increase €10.2m placing 1.7m new shares €6/share
     


The Management Board of MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, has announced today that it has successfully placed 1,700,000 new shares at EUR 6.00 per share against cash contribution with qualified investors raising proceeds in the amount of EUR 10.2 million. New shares will be issued utilizing a portion of the Authorized Capital (2013/III) representing approx. 7 percent of the registered share capital. Subscription rights of existing shareholders had been excluded.

The new shares were offered by Berenberg and Hauck & Aufhäuser Privatbankiers, acting as Joint Bookrunners in a private placement by means of an accelerated bookbuilding to qualified investors in Germany and selected countries outside of the United States, Canada, Australia and Japan.

The proceeds shall be utilized to accelerate the commercialization of NanoTherm™ Therapy outside of North America, where MagForce AG already has European regulatory approval for the treatment of Brain Tumors, and to broaden the product portfolio with further development of next generation nanoparticles. The next generation of nanoparticles provides for temperature-dependent drug release and will significantly accelerate the expansion of the treatment for other solid tumors such as Esophageal and Pancreatic Cancers.

The new shares shall be included in the Open Market of the Frankfurt Stock Exchange (Entry Standard), without publication of a prospectus, and are entitled to dividends starting from January 1, 2014.

Ben Lipps, CEO and Chairman of the Board of MagForce, commented: “The successful capital increase shows the continued trust and confidence investors put into the MagForce technology and our team. Further accelerating the commercialization of our NanoTherm™ Therapy and broadening of our product portfolio will help MagForce to unveil the full potential of its technology.”


About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan®, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.

Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list.


Disclaimer

This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of MagForce AG. No public offering of securities of MagForce AG will be made nor is a public offering intended.

This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offeror such solicitation would be prohibited. This document does not constitute an offer for the sale of of securities in the United States.

The shares of MagForce AG may not be sold or offered for sale within the United States or to or for the account or benefit of US Persons (as defined in Regulation S under the U.S. Securities Act of 1933 as amended (the "Securities Act")) unless they are registered under the Securities Act or unless they are subject to an exemption from registration. Neither MagForce AG nor any other person intend to register securities of MagForce AG or to make a public offer of securities of MagForce AG in the United States.

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

   
Record changed: 2017-04-02

Advertisement

Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for MagForce (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top